Crohn's Disease and Colitis Trial, By Invitation NCT07564609 Sponsor: University Hospital, Clermont-Ferrand Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, By Invitation

NCT07564609
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 or older who have been diagnosed with ulcerative colitis (a type of bowel disease affecting the large intestine) or Crohn's disease (another type of bowel disease).
  • People who have received at least one injection under the skin of a medicine called infliximab, after first receiving it through a drip into a vein (given at set points early in treatment).
  • People for whom infliximab was started because they were experiencing active symptoms — such as abdominal pain, frequent stools (for Crohn's disease), or a score showing active ulcerative colitis symptoms.
  • People who have been followed up for at least 3 months after starting infliximab — or, if infliximab did not work or caused problems before 3 months, people who stopped earlier for those reasons.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose bowel disease has not been clearly classified as either Crohn's disease or ulcerative colitis (sometimes called indeterminate or unclassified colitis).
  • People for whom infliximab was started specifically to treat a fistula or abscess near the back passage (isolated perianal Crohn's disease), to prevent Crohn's disease returning after bowel surgery, or to treat a severe sudden flare of colitis requiring hospitalisation.
  • People who have a permanent stoma (a surgical opening on the abdomen used to divert waste into a bag).
  • People who have had their entire large intestine removed and have had a specific type of internal pouch surgery (called an ileoanal pouch anastomosis, or IPAA).
  • People who are currently taking another biological medicine or a certain type of oral medicine (called a small molecule) alongside infliximab.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 29 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
1 October 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Steroid-free clinical remission in REMONO CD; Steroid-free clinical remission in REMONO UC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov